At enough time of acceptance, FDA considered the managed-launch formulation of OxyContin would lead to considerably lessPurdue moved forward on two paths: trying to get patents for its new drug and managing supplemental clinical trials to safe FDA approval.  Since 2009, FDA has labored with DEA and also other corporations to help educate the publi… Read More

This Article is Under Review… Read More